BusinessImmune Therapeutics, Inc. Announces Expansion of Patent PortfolioBy Nasdaq OMXMar 30, 2017, 1:46 PM UTC
BusinessImmune Therapeutics, Inc. Further Strengthens Balance Sheet as it Prepares for CommercializationBy Nasdaq OMXMar 15, 2017, 7:00 PM UTC
BusinessIMMUNE THERAPEUTICS STRENGTHENS BALANCE SHEET; Reiterates Outlook for Positive Cash Flow by Mid YearBy Nasdaq OMXFeb 9, 2017, 6:39 PM UTC
BusinessImmune Therapeutics Clears Critical Certification MilestoneBy Nasdaq OMXFeb 2, 2017, 2:40 PM UTC
BusinessUPDATE -- Immune Therapeutics Issues Special Letter to ShareholdersBy Nasdaq OMXJan 30, 2017, 3:49 PM UTC
BusinessImmune Therapeutics Issues Special Letter to ShareholdersBy Nasdaq OMXJan 30, 2017, 1:40 PM UTC
BusinessImmune Therapeutics Redeems $656,250 Convertible Note; Company Actively Working to Strengthen Balance Sheet by Year EndBy Nasdaq OMXNov 15, 2016, 2:06 PM UTC
